A Promising Era in Melanoma Treatment: Role of Combination Therapies. Issue 6 (20th April 2015)

• Record Type: Journal Article
• Authors: Nichols, Emma Hitt
• Other Names: Ribas Antoni presenter.
• Is Part Of: MD conference express. Volume 15:Issue 6(2015)
• Page Start: 2
• Page End: 3
• Publication Date: 2015-04-20
• Subjects: melanoma -- BRAF inhibitors -- MEK inhibitors -- programmed cell death 1 -- programmed death ligand 1 -- immunotherapy -- targeted therapy -- mitogen-activated protein kinase -- dermatology treatments -- dermatology clinical trials; Medicine -- Congresses; 610
• DOI: 10.1177/1559897715584551
• Languages: English
• ISSNs: 1559-8977

Abstract

Advances in melanoma research include targeted therapy with a combination of BRAF and MEK inhibitors that improves clinical outcomes, including reducing cutaneous toxicities. Anti–programmed cell death 1/programmed death ligand 1 therapy is the latest immunotherapy that produces durable responses. A combination of programmed cell death 1 blockade with BRAF inhibition led to unacceptable liver toxicity.